Notice of rescheduled AGM

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

Notice of rescheduled AGM

AGM to be held online on Thursday 18 July

Paris, France, and Eastleigh and Manchester, UK – 26 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the Company’s Annual General Meeting (AGM), due to take place earlier today, will be rescheduled and held exclusively as an open online meeting on Thursday 18 July at 1pm BST/2pm CEST.

To function as a procedural meeting, the AGM requires a sufficient number of shareholder votes to constitute a quorum to ensure the AGM is validly held in accordance with French corporate law. This threshold has not been met, therefore, in accordance with Article 19 of Novacyt articles of association, the AGM has been rescheduled. 

The agenda will remain the same as in the first convening and the AGM will comprise of both ordinary and extraordinary resolutions.

Shareholders can register to view the AGM via the online meeting platform by visiting https://reg.lumiengage.com/novacyt-sa-agm-2024/novacytagm2024/Site/Register. Registrations must be accompanied by formal evidence of shareholding.

Forms of Proxy already completed and submitted and votes cast by electronic means for the first AGM remain valid for all meetings subsequently convened with the same agenda (art. R. 225-77 of the French commercial code). Full details of dates concerning voting will follow in due course.

Contacts

     Novacyt SA                                                                                                                                      https://novacyt.com/investors

     Lyn Rees, Chief Executive Officer                                                                                                                        Via Walbrook PR

     Steve Gibson, Chief Financial Officer                                        

     SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                                              +44 (0)20 3470 0470

     Matthew Johnson / Charlie Bouverat (Corporate Finance)                            

Vadim Alexandre / Rob Rees (Corporate Broking)

    Deutsche Numis (Joint Broker)                                                                                                                   +44 (0)20 7260 1000

     Freddie Barnfield / Duncan Monteith / Michael Palser                                  

     Allegra Finance (French Listing Sponsor)                                                                                                   +33 (1) 42 22 10 10

     Rémi Durgetto / Yannick Petit                                      r.durgetto@allegrafinance.com / y.petit@allegrafinance.com 

     Walbrook PR (Financial PR & IR)                                                     +44 (0)20 7933 8780 or novacyt@walbrookpr.com

     Stephanie Cuthbert / Paul McManus /                                                        +44 (0)7796 794 663 / +44 (0)7980 541 893

     Phillip Marriage / Alice Woodings                                                                 +44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:

•       Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests

•       Precision Medicine: DPYD genotyping assay

•       Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

•       Ranger® Technology: automated DNA sample preparation and target enrichment technology

•       MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only   Range of services for the life sciences industry:

•       Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry

•       Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth (“ALNOV”).  

For more information, please refer to the website: www.novacyt.com